Orexo US Blog Contact EN About Us Key Therapeutic Areas Pharmaceuticals Digital Therapies Sustainability Investors Media OREXO INVESTORS INVESTMENT THESIS Investment thesis 1. Product portfolio addressing large and growing markets Focusing on becoming a leader in the large and growing space of mental illness and substance use disorders. In parallel, Orexo is addressing the ongoing opioid epidemic, one of the largest health cri­ses to take place in the US and a growing global concern. 2. Strong cash conversion to support growth Lead product ZUBSOLV®, for the treatment of opioid use disorder, is a strong cash and profit contributor, enabling continued investment in on-market products, and R&D. 3. Leveraging our US commercial excellence Strategic focus on leveraging its commercial excellence and strong market access network in the US, by adding more products to the US commercial platform. 4. Pipeline targeting unmet medical needs Continue to build on the strong experience of developing products with worldwide approval by expanding the pipeline with multiple short-time to market assets based on innovative drug delivery and digital technologies, addressing unmet medical needs. 5. Entering digital therapeutics, a new evidence-based frontier in patient care Digital therapeutics increase access to treatment and improve treatment outcomes, and is set to become an integral part of the global healthcare landscape. Mental illness and substance use disorders are areas where it is most needed. Thanks and welcome back! ©2021 Orexo AB (publ.) – All rights reserved Contact | Dictionary & Definitions | Privacy Policy | Legal notice | Cookie policy

Orexo US Blog Contact EN About Us Key Therapeutic Areas Pharmaceuticals Digital Therapies Sustainability Investors Media OREXO ABOUT US MEET US Meet our employees Mikaela Odlander Geri-Lynn Utter Mattias Liljestrand Lee R. Marks Mikaela Odlander Director of Digital Therapeutics As Director of Digital Therapeutics at Orexo my focus is to help build out the Digital Therapies Business Unit together with my team. This means that I primarily work on the US launch and go-to-market strategies for the DTx portfolio, and business development strategies Ex-US. I hold a BSc in International Business from Gothenburg School of Economics and an MSc in Management from UCL in London. Why have you chosen to work for Orexo? What is the best thing about working for Orexo? What is the hardest part of your job? What are your main challenges in the coming year? Thanks and welcome back! ©2021 Orexo AB (publ.) – All rights reserved Contact | Dictionary & Definitions | Privacy Policy | Legal notice | Cookie policy